Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.24.3
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Product Information [Line Items]        
Total net revenue $ 2,350,386 $ 298,484 $ 7,154,429 $ 319,143
Total operating loss (1,973,864) (2,294,504) (6,006,892) (5,630,823)
Non-operating income (expense), net (24,417) 5,914 (54,392) 85,676
Net loss before income tax expense (1,998,281) (2,288,590) (6,061,284) (5,545,147)
Income tax expense (2,559) (2,294) (11,650) (18,700)
Net loss (2,000,840) (2,290,884) (6,072,934) (5,563,847)
Diagnostic R&D [Member]        
Product Information [Line Items]        
Total net revenue 1,731 14,250 8,654 14,250
Total operating loss (368,202) (436,799) (1,264,696) (1,196,428)
Laboratory Services [Member]        
Product Information [Line Items]        
Total net revenue [1] 2,348,655 284,234 7,145,775 304,893
Total operating loss (2,150,825) (307,172) (7,423,109) (308,493)
General Corporate Activities [Member]        
Product Information [Line Items]        
Total operating loss $ (1,805,223) $ (1,849,017) $ (4,473,516) $ (4,445,045)
[1] The majority of the increase versus the prior year is from the acquisition of the clinical pathology laboratory on September 18, 2023.